DrugPatentWatch Database Preview
Patent: 9,314,154
» See Plans and Pricing
Summary for Patent: 9,314,154
| Title: | System and method for providing analysis of visual function using a mobile device with display |
| Abstract: | A visual function evaluation is performed using a sequence of interactions with a mobile device. A patient user may perform a variety of visual tests using the mobile device. The mobile device transmits the test results to a remote server implementing analysis of the visual function results using network service. The network service receives the test results, processes the results, and provides the processed results to a healthcare provider. The processed results may include trends of the user\'s visual function test performance. The healthcare provider, such as a physician, may optimize and administer treatment based on the data. Early detection of changes in visual function can enable the healthcare provider to individualize treatment, helping to prevent vision loss while minimizing visits to the office, discomfort, and expense. |
| Inventor(s): | Palanker; Daniel (Palo Alto, CA), Blumenkranz; Mark (Los Altos Hills, CA) |
| Assignee: | The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA) |
| Application Number: | 14/352,571 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,314,154
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | LUCENTIS | ranibizumab | INJECTABLE; INJECTION | 125156 | 001 | 2006-06-30 | Start Trial | The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA) | 2031-10-17 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA) | 2031-10-17 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA) | 2031-10-17 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,314,154
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013059331 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2014022850 | Start Trial |
| United States of America | 10702140 | Start Trial |
| United States of America | 2014285769 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
